Catalent goes public in a successful IPO
Blackstone Group-owned CDMO nets over $800 million
Catalent Inc. (Somerset, NJ), spun out of Cardinal Health back in 2007, has now taken the “next step in our growth journey” by going public, at CTLT on the New York Stock Exchange. Blackstone Group, the private investment firm which acquired most of the business, will retain majority ownership. The money raised will be used primarily to retire debt the company has undertaken in the past few years.
Catalent’s financial filings indicate the company grossed about $1.8 billion in 2013, in three business segments: Oral Technologies (about 66% of revenue). Medication Delivery Solutions (about 12%) and Development and Clinical Services (about 22%). That makes it a leader in clinical development and manufacturing organizations (CDMOs) globally. The oral technologies group has 14 manufacturing and development plants, located globally. Recent investments include expansions in its Softgel and clinical supply business in China and Brazil, a new Biologics Center of Excellence in Madison, WI and an expansion of its oral technologies manufacturing site in Winchester, KY.
Protecting Temperature-Sensitive Pharmaceuticals, Without Unnecessary Plastic Waste
March 24th 2025Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.
